Condition: Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) · Sponsor: Hellenic Cooperative Oncology Group
This is multicenter, prospective, open label, non-interventional study that will collect real-world data (RWD) on the clinical efficacy and safety of NalIriFOx as a first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).
This description comes directly from the study's public registry record.
Ioanna Mitrentsi, PhD · +30 2106912520 · i_mitrentsi@hecog.ondsl.gr
Maria Moschoni · +30 2106912520 · m_moschoni@hecog.ondsl.gr
Always discuss trial participation with your own doctor first.
| Attikon University General Hospital | Athens, Greece | Recruiting |
| General Oncology Hospital Agioi Anargyroi | Athens, Greece | Recruiting |
| HYGEIA Hospital | Athens, Greece | Recruiting |
| HYGEIA Hospital | Athens, Greece | Recruiting |
| 2nd Oncology Department, Metropolitan Hospital | Athens, Greece | Recruiting |
| Ippokratio | Athens, Greece | Recruiting |
| Larissa University General Hospital | Larissa, Greece | Recruiting |
| General Hospital Agios Andreas | Pátrai, Greece | Recruiting |
| Thessaloniki General Hospital "George Papanikolaou" | Thessaloniki, Greece | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07723261